Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 65

Fluorescent Probe for Real-Time Kidney Function in Critically Ill Adults

Official title: Fluorescent Probe for Assessment of Renal Elimination

Run by University of Kentucky · NCT07643467 · Data updated 2026-11-12

Aging and illness can make kidney tests less reliable, so this study tests a new real-time kidney function device to see if it matches standard methods in critically ill adults.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment200 (estimated)
SponsorUniversity of Kentucky
Academic / other
Locations1 site (Lexington, Kentucky)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedMay 31, 2028
Study endsJune 30, 2028
Registry record updatedOctober 7, 2026
Trial IDNCT07643467 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18-65 who are critically or acutely ill and currently in the ICU with stable renal function.

Probably not a fit

Patients with unstable kidney function (KDIGO AKI stages 1-3) or other specified exclusions may not benefit from this device.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional phase 4 study evaluates the tGFR device, Relmapirazin, Iohexol, and the Medibeacon tGFR monitor against traditional urine collection and creatinine-based methods. It aims to determine how well the real-time transdermal GFR measurement aligns with accepted kidney function assessments in hospitalized, acutely ill patients. Participants are adults 18-65 who are critically or acutely ill and admitted to the ICU, with stable renal function. The study explores whether real-time kidney monitoring can improve dosing of renally eliminated medications in this population.

Why it matters

Potential benefit: If successful, patients may receive more accurate, timely medication dosing and improved management of kidney function.

How similar studies have gone: Prior methods of real-time kidney assessment show promise, but this approach with a transdermal device and multiple comparators is relatively novel in acutely ill patients.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18-65 years old
* critically ill or acutely ill hospitalized patients admitted to the intensive care unit
* Stable/normal renal function

Exclusion Criteria:

* Prisoners
* Pregnant women
* Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr \> 1.5x baseline)

Where it's running

  • UKHealthCare/University of Kentucky
    Lexington, Kentucky, United States
    Recruiting

Study contacts

  • Principal investigator: Aaron M Cook, PharmD — University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
  • Study coordinator: Aaron Cook, PharmD
  • Email: amcook0@uky.edu
  • Phone: 18592578444

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.